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Abstract
Objective To determine whether people who donate a kidney have an
increased risk of cardiovascular disease.
Design Retrospective population based matched cohort study.
Participants All people who were carefully selected to become a living
kidney donor in the province of Ontario, Canada, between 1992 and
2009. The information in donor charts was manually reviewed and linked
to provincial healthcare databases. Matched non-donors were selected
from the healthiest segment of the general population. A total of 2028
donors and 20 280 matched non-donors were followed for a median of
6.5 years (maximum 17.7 years). Median age was 43 at the time of
donation (interquartile range 34-50) and 50 at the time of follow-up
(42-58).
Main outcome measures The primary outcome was a composite of
time to death or first major cardiovascular event. The secondary outcome
was time to first major cardiovascular event censored for death.
Results The risk of the primary outcome of death and major
cardiovascular events was lower in donors than in non-donors (2.8 v 4.1
events per 1000 person years; hazard ratio 0.66, 95% confidence interval
0.48 to 0.90). The risk of major cardiovascular events censored for death
was no different in donors than in non-donors (1.7 v 2.0 events per 1000
person years; 0.85, 0.57 to 1.27). Results were similar in all sensitivity
analyses. Older age and lower income were associated with a higher
risk of death and major cardiovascular events in both donors and
non-donors when each group was analysed separately.
Conclusions The risk of major cardiovascular events in donors is no
higher in the first decade after kidney donation compared with a similarly
healthy segment of the general population. While we will continue to
follow people in this study, these interim results add to the evidence
base supporting the safety of the practice among carefully selected
donors.
Introduction
In the general population there is a robust association between
reducedkidneyfunctionandanincreasedriskofcardiovascular
disease.
1 It is possible that this risk could apply to the over 27
000 registered people who donate a kidney worldwide each
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RESEARCHyear.
2 Donors lose half their renal mass, and, similar to reduced
kidney function for other reasons, donor nephrectomy can
increase blood pressure and metabolites such as uric acid.
3 4
These physiological markers, however, might not be valid
surrogates in donors for the clinically relevant outcomes that
patients and their providers are most interested in.
Cardiovasculardiseaseisakeyeventofinterestandisaleading
causeofdeath.Fivestudieshaveconsideredtheriskofallcause
mortalityafterkidneydonation(studiesfromtheUnitedStates,
Sweden, Norway, and Japan.
5-9) Reassuringly, all five showed
no evidence of increased long term mortality among kidney
donors. One of these studies also found no higher risk of
cardiovascular mortality.
8 In a preliminary study we also found
no evidence of a higher risk of major cardiovascular events in
1278peoplewhodonatedakidney.
10Limitationsoftheanalysis
with respect to study size and characteristics of the matched
non-donors, however, meant that uncertainties persisted with
these findings.
11-13
We conducted a study that dealt with many of the previous
limitations. We manually reviewed the medical charts of over
2000 living kidney donors in the largest province in Canada,
linked this information to universal healthcare databases to
reliably identify major cardiovascular events long term with
little loss to follow-up, and used methods of restriction and
matching to select the healthiest segment of the general
populationwithwhichdonoroutcomescouldbecompared.We
also performed subgroup analyses according to the year of
nephrectomy (duration of follow-up) to identify any trends in
riskwithalongerperiodoffollow-up.Wedidthisstudybecause
betterknowledgeofmajorcardiovasculareventsinpeoplewho
become living kidney donors maintains public trust in the
transplantation system, informs the choices of potential donors
andrecipients,andguidesfollow-upcaretomaintaingoodlong
term health.
Methods
Design and setting
We conducted a population based matched cohort study in
Ontario, Canada. Ontario currently has about 13 million
residents.
14Residentshaveuniversalaccesstohospitalcareand
physicianservices.Thereportingofthisstudyfollowsguidelines
set out for observational studies.
15
Data sources
We ascertained personal characteristics, covariate information,
and outcome data from records in four databases. Trillium Gift
of Life is Ontario’s central organ and tissue donation agency.
Thisdatabaseisuniqueinthatitcapturedinformationonliving
kidney donors in the province at the time of donation. We
manually reviewed the medical charts of all people who
underwentdonornephrectomyatallfivemajortransplantcentres
in Ontario between 1992 and 2009 to ensure the accuracy of
donor information in the Trillium database. The Canadian
Institute for Health Information Discharge Abstract Database
(CIHI-DAD) records detailed diagnostic and procedural
information for all admissions to hospital in Ontario. The
Ontario Health Insurance Plan database (OHIP) contains all
health claims for inpatient and outpatient physician services.
The Ontario Registered Persons Database (RPDB) contains
demographic and vital status information on all Ontario
residents. These databases have been used extensively to
researchhealthoutcomesandhealthservices.
16-20Thedatabases
were essentially complete for all variables used in this study.
Population
We included all living kidney donors who were permanent
residents of Ontario. The date of the nephrectomy served as the
start date for donor follow-up and was designated the index
date. Choosing the best type of non-donors with which donors
can be compared is central to any study of relative risks
associated with donor nephrectomy.
21 Donors go through a
detailed selection process and are inherently healthier than the
general population. We used techniques of restriction and
matching to select the healthiest segment of the general
population. We randomly assigned an index date to the entire
adult general population according to the distribution of index
datesindonors.Wethenidentifiedcomorbiditiesandmeasures
ofaccesstohealthcarefromthebeginningofavailabledatabase
records(1July1991)totheindexdate.Thisprovidedanaverage
of 11 years of medical records for baseline assessment, with
99% of people having at least two years of baseline data for
review. Among the general population we excluded any adult
with any medical condition before the index date that could
preclude donation. This included evidence of diagnostic,
procedural, or visit codes for any of genitourinary disease,
diabetes, hypertension, cancer, cardiovascular disease,
pulmonary disease, liver disease, rheumatological conditions,
chronic infections, a history of nephrology consultation, and
evidence of frequent physician visits (more than four visits in
theprevioustwoyears).Wealsoexcludedanypersonwhofailed
toseeaphysicianatleastonceinthetwoyearsbeforetheindex
date(giventhatOntariohasashortageofphysicianswewanted
to ensure that non-donors had evidence of access for routine
healthcare needs including preventative health measures; we
conducted a sensitivity analysis in which we removed this
exclusion and the study results were not materially different).
From a total of 9 643 344 adult Ontarians during the period of
interest, our selection procedures resulted in the exclusion of
85% of adults (n=8 216 038). From the adults remaining we
thenmatched10non-donorstoeachdonor.Wematchedonage
(within two years), sex, index date (within six months), rural
(population less than 10 000) or urban residence, and income
(categorised into fifths of average neighbourhood income on
the index date).
Outcomes
All people were followed until 31 March 2010 or emigration
from the province. The primary outcome was a composite of
time to death or first major cardiovascular event (myocardial
infarction, stroke, coronary angioplasty, coronary bypass
surgery, carotid endarterectomy, repair of abdominal aortic
aneurysm,orperipheralvascularbypasssurgery).Thesecondary
outcomesweretimetofirstmajorcardiovasculareventcensored
for death and components of the primary outcome analysed
separately.Theseoutcomesweredefinedbyusingcodesproved
to have good validity when compared with chart review (see
appendix on bmj.com). We examined the characteristics
associated with death and first major cardiovascular event
separatelyindonorsandnon-donors.Thesecharacteristicswere
age (per five years), sex, rural or urban residence, income fifth,
and year of index date (per year).
Statistical analysis
We assessed differences in baseline characteristics between
donors and non-donors using standardised differences.
22 23 This
metric describes differences between group means relative to
the pooled standard deviation; differences greater than 10%
reflect the potential for meaningful imbalance. We used a two
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RESEARCHsided log rank test stratified on matched sets to compare
differences in death and cardiovascular outcomes between
donors and non-donors. We used Cox regression stratified on
matchedsetstocalculatethehazardratioswith95%confidence
intervals. The proportional hazards assumption was met
(non-significantdonor×follow-uptimeinteractionterm,P=0.27).
Werepeatedtheprimaryanalysisinfourprespecifiedsubgroups
defined by the median age at the index date (≤55 v >55), sex,
first degree relative with kidney failure, and index date
(1992-2001 (median follow-up 11.4 years, interquartile range
9.5-13.8) v 2002-9 (4.0 years, 2.4-4.8)). We defined subgroups
bythecharacteristicindonors,withnon-donorsfollowingtheir
matched donor. We examined whether hazard ratios differed
among subgroups using a series of pairwise standard z tests.
24
We examined the characteristics associated with a first major
cardiovasculareventseparatelyindonorsandnon-donorsusing
Cox regression. We conducted all analysis with SAS software
version 9.2.
Results
Baseline characteristics
Table1showsthebaselinecharacteristicsfor2028livingkidney
donors and 20 280 matched non-donors⇓. The median age was
43 (interquartile range 34-50), and 60% were women. As
expected, donors had more physician visits in the year before
the index date than non-donors because such visits are a
necessary part of the evaluation process.
Mostlivingkidneydonorsweresiblingsoftherecipients(35%),
followedbyspouses(19%),parents(14%),andchildren(13%).
Nearly half (43%) of the nephrectomies were performed
laparoscopically,andtherestweredonewithanopenprocedure.
Before donation, the median serum creatinine was 77 µmol/L
(interquartile range 66-86 µmol/L) (equivalent to 0.87 mg/dL,
0.75-0.97 mg/dL) and the estimated glomerular filtration rate
(eGFR) was 97 mL/min/1.73 m
2 (86-109) (with the Chronic
Kidney Disease Epidemiology Collaboration formula
(CKD-EPI).
25 The median length of follow-up was 6.5 years
(6.8 years in donors, 6.4 years in non-donors, maximum 17.7
years). A total of 609 donors and 5744 non-donors were
followed for a period of 10 years or more. The median age at
the time of last follow-up for the entire cohort was 50 (42-58).
Of the 22 308 individuals (2028 donors, 20 280 non-donors),
20 450 (91.7%) were alive at the end of study follow-up (31
March 2010) and had not experienced a major cardiovascular
event, and 1206 (5.4%) were censored at a time of emigration
fromtheprovince(48(2.4%)donors,1158(5.7%)non-donors).
Thetotalpersonyearsoffollow-upwas162508(15176donors,
147 332 non-donors).
Outcomes
Figure 1 and table 2 present the main outcomes⇓⇓. There were
381 deaths (16 donors, 365 non-donors) and 313 major
cardiovascular events (26 donors, 287 non-donors). The risk of
death or first major cardiovascular event was lower in donors
than in non-donors (2.1% v 3.0%; 2.8 v 4.1 events per 1000
person years; hazard ratio 0.66, 95% confidence interval 0.48
to 0.90; log rank P=0.01). Table 2 shows the types of
cardiovascular events⇓. There was no significant difference in
the risk of major cardiovascular events censored for death
between donors and non-donors (1.3% v 1.4%, 1.7 v 2.0 events
per 1000 person years; hazard ratio 0.85, 0.57 to 1.27). Figure
2 shows the subgroup analyses⇓. An earlier index date (longer
period of follow-up) did not influence the association between
kidney donation and the primary outcome, nor did older age at
index date, sex, or history of a first degree biological relative
with kidney failure (P value for interaction ranged from 0.10 to
0.48). Subgroup results were similar for the outcome of time to
first major cardiovascular event censored for death. Older age
and lower income were associated with a higher risk of death
or first major cardiovascular event in both donors and
non-donors when each group was examined separately (table
3)⇓.
Discussion
The risk of major cardiovascular events in people who donate
a kidney is no higher in the first decade after transplantation
than in matched non-donors. There is no trend of increased
cardiovascular risk in subgroups of donors with a longer
(compared with shorter) period of follow-up, nor do Kaplan
Meier curves after 10 years of follow-up suggest any higher
riskofdeathormajorcardiovasculareventsindonorscompared
with non-donors.
We conducted this study to determine whether people who
donate a kidney have a higher risk of cardiovascular disease
than a similarly healthy segment of the general population.
While we will continue to follow up people in this study, these
interimresultsprovideimportantsafetyreassurancestodonors,
theirrecipients,andtransplantprofessionals.Reassuringly,with
longer follow-up the observed risk for the primary outcome
continued to be lower in donors than in non-donors. As stated
by others, we attribute this lower risk to the rigorous selection
process of establishing excellent health before donation, which
includes psychological assessment and counselling, abdominal
imaging, cancer screening, and an assessment for chronic
infectious diseases.
7 Healthy lifestyle behaviours are also
emphasised at this time. Restriction of non-donors to the
healthiest segment of the general population, as done in this
study, still did not replicate this process.
Strengths and limitations of study
Ouranalysesmeaningfullyassessedmajorcardiovascularevents
in previous kidney donors.
10 We were able to do this because
of the universal healthcare benefits in the province of Ontario,
with the collection of all healthcare encounters for all citizens.
This reduces concerns about selection and information biases.
Asmentioned,forthepresentstudywemanuallyreviewedover
2000consecutivemedicalchartstoensuretheaccuracyofdonor
informationpresentedinthisstudy.Thelargenumberofdonors
and non-donors provided good precision for the estimates we
provide. Outcomes of death and major cardiovascular events
were ascertained in a reliable and valid manner in our data
sources. Loss to follow-up, a concern in many long term
follow-up studies of donors, was minimal in our setting (less
than 6% of people emigrated from the province during
follow-up). Our data, however, are not without limitations.
Causeofdeathcouldnotbereliablyassessedinourdatasources.
Our results describing major cardiovascular events, however,
are consistent with a study from Norway that showed no higher
riskofcardiovascularmortalityinpeoplewhodonatedakidney
compared with the general population (median follow-up 14.3
years from nephrectomy).
8 Accurate racial information was not
available. Given that 75% of Ontario residents are white, these
results might generalise less well to non-white donors.
26 The
acceptance criteria of living donors in our region during the
period of review were quite stringent.
27 Thus, these data should
not be generalised to the recent practice of accepting donors
with health conditions such as obesity or hypertension.
28
Information on kidney function and family history of kidney
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RESEARCHdiseasewereunavailableinnon-donors,andmeasurementssuch
as blood pressure and body mass index (BMI) before
transplantationwereunavailableinbothdonorsandnon-donors.
This information might have allowed for better selection of
non-donors. Collection of such information in the number of
individualsneededtoadequatelyexaminecardiovascularevents
in our setting, however, would have been prohibitively
expensive, with results unavailable for another decade. Finally,
we did not have data on glomerular filtration rate in donors
during follow-up, which precluded an assessment of
cardiovascular risk according to this feature.
Comparison with other studies
A collaborative meta-analysis of multiple general population
non-donor cohorts has recently summarised the association
between reduced kidney function and cardiovascular disease.
1
Over a median follow-up of eight years, the risk of
cardiovascular mortality increases with a lower estimated
glomerular filtration rate. Compared with an estimated
glomerular filtration rate of 90-104 mL/min/1.73 m², hazard
ratios for cardiovascular mortality are 1.03 (95% confidence
interval0.85to1.24)foranestimatedrateof75-89mL/min/1.73
m², 1.09 (0.92 to 1.29) for an estimated rate of 60-74
mL/min/1.73 m², 1.52 (1.18 to 1.97) for an estimated rate of
45-59mL/min/1.73m²,and2.04(1.80to3.21)foranestimated
rate of 30-44 mL/min/1.73 m². Similar associations with
narrower confidence intervals are seen for all cause mortality.
Concurrent evidence of albuminuria increases these risks. In
the donor setting, about 10% of individuals show 300 mg or
more of proteinuria a day in the decade after donation. Donors
are more likely to develop microalbuminuria than the general
population. In addition, in the decade after donation 40% of
people who donate a kidney have a glomerular filtration rate of
60-80 mL/min/1.73 m² and 10% have a of 30-59 mL/min/1.73
m².
29 30
So how does one reconcile the lack of observed risk of
cardiovasculardiseaseamonglivingdonorsinthecurrentstudy
with the observed risk among individuals with reduced
glomerularfiltrationrateingeneralpopulationcohorts?Firstly,
the association seen in the general population might not be
causal. It might, for example, reflect systemic atherosclerosis
related to diabetes, hypertension, and older age, which coexist
with reduced glomerular filtration rate but which are not fully
accountedforinmultivariablemodels.Ontheotherhand,donors
develop reduced glomerular filtration rate and low grade
proteinuria through a non-pathological process, which might
not carry the same prognostic relevance. Secondly, the process
of donor evaluation is used to select individuals who are in
excellent health with good long term prognosis. In our setting,
follow-uphealthcareisauniversalbenefittoallCanadians,and
we have previously confirmed that donors tend to have more
have routine primary healthcare visits in follow-up than
non-donors.
10 These elements of healthcare, which can include
early detection and management of cardiovascular risk factors,
could offset any increase in risk of cardiovascular disease
attributabletoreducedglomerularfiltrationrate.Ifunmeasured
baseline cardiovascular risk factors were more prevalent in
non-donors than donors in our study, however, this could have
masked evidence of an increased risk of cardiovascular disease
in donors. For these reasons it remains prudent to counsel all
donors on modifiable risk factors that prevent future
cardiovascular disease both before and after the donation
process.Inourstudythenon-modifiablefactorofolderageand
the difficult to modify factor of low income were similarly
associated with death and cardiovascular events in donors and
non-donors. Finally, it is possible that an association between
living donation and risk of cardiovascular disease does exist
but takes much longer to manifest. It might depend on more
donorsenteringanolderagerangeandmanifestingaglomerular
filtration rate less than 60 mL/min/1.73 m
2 in the decades after
donation. For this reason, ongoing follow-up of this and other
donor cohorts is warranted.
Conclusion
Taken together with other studies that have shown no increase
in mortality in the decades after kidney donation, the present
study adds to the available evidence base supporting the safety
of the practice among carefully selected donors.
27 The results
do not provide evidence to justify relaxing the rigorous criteria
used to select people who become kidney donors.
We thank Ping Li and Nelson Chong from the Institute for Clinical
Evaluative Sciences, and Frank Markel, Versha Prakash, and Keith
Wong from Trillium Gift of Life Network for their support. We also thank
Laura Agar, Nishant Fozdar, Mary Salib, and Robyn Winterbottom, who
abstracted data from medical charts at five transplant centres for this
project.
DonorNephrectomyOutcomeResearch(DONOR)NetworkInvestigators
Jennifer Arnold, Neil Boudville, Ann Bugeya, Christine Dipchand, Mona
Doshi, Liane Feldman, Amit Garg, Colin Geddes, Eric Gibney, John
Gill, Martin Karpinski, Joseph Kim, Scott Klarenbach, Greg Knoll, Ngan
Lam, Charmaine Lok, Philip McFarlane, Mauricio Monroy-Cuadros,
Norman Muirhead, Immaculate Nevis, Christopher Y Nguan, Chirag
Parikh, Emilio Poggio, G V Ramesh Prasad, Jessica Sontrop, Leroy
Storsley, Ken Taub, Sonia Thomas, Darin Treleaven, Ann Young.
Contributors: All authors contributed to study design, data collection,
data analysis and interpretation, and revising the paper. AXG is
guarantor.
Funding: This project was conducted at the Institute for Clinical
Evaluative Sciences (ICES). ICES is funded by an annual grant from
the Ontario Ministry of Health and Long-Term Care (MOHLTC). AXG
was supported by a Canadian Institutes of Health Research
Clinician-Scientist Award. GK was supported by a University of Ottawa
Chair in Clinical Transplantation Research. SK was supported by the
Alberta Heritage Foundation for Medical Research/Alberta Innovates
Health Solutions, a joint initiative between Alberta Health and Wellness
and the University of Alberta. The opinions, results and conclusions
reported in this paper are those of the authors and are independent of
the funding sources. The funding sources did not influence any aspect
of this study.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: This study was conducted according to a prespecified
protocol, which was approved by the research ethics board at the
Sunnybrook Health Sciences Centre (Toronto, ON, Canada).
Data sharing: No additional data available.
1 Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al.
Association of estimated glomerular filtration rate and albuminuria with all-cause and
cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
Lancet 2010;375:2073-81.
2 Horvat LD, Shariff SZ, Garg AX. Global trends in the rates of living kidney donation. Kidney
Int 2009;75:1088-98.
3 Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, et al.
Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med
2006;145:185-96.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1203 doi: 10.1136/bmj.e1203 (Published 1 March 2012) Page 4 of 10
RESEARCHWhat is already known on this topic
Each year over 27 000 people around the world become a kidney donor, and the number is increasing in response to a shortage of
kidneys for transplantation from deceased donors
In the general population there is a robust association between reduced kidney function and an increased risk of cardiovascular disease
Similar to reduced kidney function for other reasons, donor nephrectomy could increase blood pressure, which is a potent risk factor for
cardiovascular disease
What this study adds
The risk of major cardiovascular events was no higher in the first decade after people had donated a kidney than in a similarly healthy
segment of the general population
The results add to the evidence base supporting the safety of the practice among carefully selected donors
4 Young A, Nevis IF, Geddes C, Gill J, Boudville N, Storsley L, et al. Do biochemical
measures change in living kidney donors? A systematic review. Nephron Clin Pract
2007;107:c82-9.
5 Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, et al. Long-term consequences
of kidney donation. N Engl J Med 2009;360:459-69.
6 Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, et al. Perioperative
mortality and long-term survival following live kidney donation. JAMA 2010;303:959-66.
7 Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors live
longer. Transplantation 1997;64:976-8.
8 Mjoen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, et al. Overall and
cardiovascular mortality in Norwegian kidney donors compared to the background
population. Nephrol Dial Transplant 2012;27:443-7.
9 Okamoto M, Akioka K, Nobori S, Ushigome H, Kozaki K, Kaihara S, et al. Short- and
long-term donor outcomes after kidney donation: analysis of 601 cases over a 35-year
period at Japanese single center. Transplantation 2009;87:419-23.
10 Garg AX, Prasad GV, Thiessen-Philbrook HR, Ping L, Melo M, Gibney EM, et al.
Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health
administrative data in Ontario, Canada. Transplantation 2008;86:399-406.
11 Tan L, Tai BC, Wu F, Raman L, Consigliere D, Tiong HY. Impact of Kidney Disease
Outcomes Quality Initiative guidelines on the prevalence of chronic kidney disease after
living donor nephrectomy. J Urol 2011;185:1820-5.
12 Tomic A, Jevtic M, Novak M, Ignjatovic L, Zunic G, Stamenkovic D. Changes of glomerular
filtration after nephrectomy in living donor. Int Surg 2010;95:343-9.
13 Haynes R, Landray MJ, Winearls CG. Reassuring results with regard to the effect of donor
nephrectomy on cardiovascular outcomes. Nat Clin Pract Nephrol 2009;5:126-7.
14 Statistics Canada. Population by sex and age group, by province and territory. 2010.
www40.statcan.gc.ca/l01/cst01/demo31a-eng.htm.
15 Von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
16 Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to
invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J
Med 1999;341:1359-67.
17 Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement
therapy in Ontario before and after publication of the Women’s Health Initiative Study.
JAMA 2003;289:3241-2.
18 Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions
among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
19 Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of
hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J
Med 2004;351:543-51.
20 Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2
inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart
failure outcomes in elderly patients: a population-based cohort study. Lancet
2004;363:1751-6.
21 Lin J, Kramer H, Chandraker AK. Mortality among living kidney donors and comparison
populations. N Engl J Med 2010;363:797-8.
22 Austin PC. Using the standardized difference to compare the prevalence of a binary
variable between two groups in observational research. Commun Stat Simul Comput
2009;38:1228-34.
23 Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al. Reader’s guide
to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ
2005;330:960-2.
24 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ
2003;326:219.
25 Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative
performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of
Diet in Renal Disease (MDRD) study equations for estimating GFR levels above 60
mL/min/1.73 m
2. Am J Kidney Dis 2010;56:486-95.
26 Statistics Canada. Population Groups (28) and Sex (3) for the Population of Canada,
Provinces, Territories, Census Metropolitan Areas and Census Agglomerations, 2006
Census—20% Sample Data. 2011. www.statcan.gc.ca.
27 Delmonico F. A report of the Amsterdam forum on the care of the live kidney donor: data
and medical guidelines. Transplantation 2005;79(6 suppl):S53-66.
28 Young A, Storsley L, Garg AX, Treleaven D, Nguan CY, Cuerden MS, et al. Health
outcomes for living kidney donors with isolated medical abnormalities: a systematic review.
Am J Transplant 2008;8:1878-90.
29 Ibrahim HN, Rogers T, Tello A, Matas A. The performance of three serum creatinine-based
formulas in estimating GFR in former kidney donors. Am J Transplant 2006;66:1479-85.
30 Garg AX, Muirhead N, Knoll G, Yang RC, Prasad GV, Thiessen-Philbrook H, et al.
Proteinuria and reduced kidney function in living kidney donors: a systematic review,
meta-analysis, and meta-regression. Kidney Int 2006;70:1801-10.
Accepted: 03 January 2012
Cite this as: BMJ 2012;344:e1203
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1203 doi: 10.1136/bmj.e1203 (Published 1 March 2012) Page 5 of 10
RESEARCHTables
Table 1| Characteristics of kidney donors and non-donors at time of transplantation*. Figures are numbers (percentage) unless stated
otherwise
Non-donors (n=20 280) Donors (n=2028)
43 (34-50) 43 (34-50) Median (IQR) age (years)
12 160 (60) 1216 (60) Women
Income fifth:
3010 (15) 301 (15) Lowest
4300 (21) 430 (21) Middle
4700 (23) 470 (23) Highest
2780 (14) 278 (14) Rural town
1 (0-2) 11 (8-15) Median (IQR) No of visits to physician in previous year†
Year:
2170 (11) 217 (11) 1992-5
5315 (26) 531 (26) 1996-2000
6833 (34) 683 (34) 2001-5
5962 (29) 597 (29) 2006-9
IQR=interquartile range.
*Also referred to as index date, randomly assigned to non-donors to establish start of time follow-up.
†Indicates standardised difference between donors and non-donors >10%. Standardised differences are less sensitive to sample size than traditional hypothesis
tests. They provide measure of difference between groups divided by pooled SD; value >10% is interpreted as meaningful difference between groups. As expected,
donors had more physician visits in year before index date than non-donors, as such visits are necessary for donor evaluation process.
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RESEARCHTable 2| Death or major cardiovascular events among kidney donors and non-donors
Non-donors (n=20 280) Donors (n=2028)
6.4 (3.5 to 10.6) 6.8 (3.7 to 10.9) Median (IQR) follow-up (years)
0.1-17.7 0.5-17.7 Range follow-up (years)
147 332 15 176 Total follow-up (person years)
610 (3.0) 42 (2.1) No (%) of events
4.1 2.8 No of events per 1000 person years*
1.0 (reference) 0.66 (0.48 to 0.90) Model based risk ratios (95% CI)
No (%) of types of events†:
365 (1.8) 16 (0.8) Death
141 (0.7) 14 (0.7) Acute myocardial infarction
179 (0.9) 15 (0.7) Coronary artery angioplasty or surgery
51 (0.2) 5 (0.2) Stroke
IQR=interquartile range.
*P=0.01, stratified log rank test.
†Events of carotid endarterectomy, abdominal aortic aneurysm repair, and peripheral vascular bypass surgery were rare (≤25 events for all three outcomes
combined for donors and non-donors combined) and are not reported here for reasons of privacy. Events reported here are not mutually exclusive; individual might
have had more than one event in follow-up. In survival models we considered time to first event.
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RESEARCHTable 3| Risk factors for death or major cardiovascular events in kidney donors and non-donors* when each group was analysed separately.
Figures are rate ratios (95% CI)
Non-donors Donors
Death or major cardiovascular event
1.61 (1.55 to 1.68) 1.44 (1.25 to 1.66) Older age (per 5 years)†
0.43 (0.37 to 0.51) 0.73 (0.40 to 1.33) Women (v men)
1.06 (0.86 to 1.32) 0.58 (0.21 to 1.62) Rural residence (v urban residence)
0.85 (0.80 to 0.90) 0.77 (0.61 to 0.96) Higher income fifth (per fifth)
0.99 (0.96 to 1.01) 0.97 (0.88 to 1.08) More recent year of index (per year)
Major cardiovascular event (death censored)
1.60 (1.51 to 1.69) 1.47 (1.23 to 1.75) Older age (per 5 years)†
0.27 (0.21 to 0.35) 0.57 (0.26 to 1.23) Women (v men)
1.23 (0.91 to 1.65) 0.70 (0.21 to 2.34) Rural (v urban) residence
0.86 (0.79 to 0.93) 0.83 (0.63 to 1.10) Higher income fifth (per fifth)
0.98 (0.94 to 1.01) 0.92 (0.81 to 1.04) More recent year of index (per year)
*Separate multivariable Cox regression models created for kidney donors and non-donors.
†Refers to individual’s age at beginning of follow-up (also referred to as index date or cohort entry date).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1203 doi: 10.1136/bmj.e1203 (Published 1 March 2012) Page 8 of 10
RESEARCHFigures
Fig 1 Kaplan-Meier estimates of survival probability without death or major cardiovascular event (top) and without major
cardiovascular event (censored for death, bottom)
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RESEARCHFig 2 Influence of age, sex, index date (duration of follow-up), and relative with kidney failure on risk of death or first major
cardiovascular event (top) and first major cardiovascular event (censored for death, bottom). Individuals with index date of
1992-2001 had median follow-up 11.4 years (interquartile range 9.5-13.8); individuals with index date of 2002-9 had median
follow-up 4.0 years (2.4 to 5.8)
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